What 19 Years With GIST Has Taught Me
Ed shares his 19-year survivor journey of resilience, multiple surgeries, evolving treatments with the support of family, expert doctors, and advocacy resources that helped him continue moving forward with hope.
Miami Precision Biannual Conference
A meaningful reflection on connection, self-advocacy, and the power of community at the Miami Precision Biannual Conference.
Patient of the Month – May 2026: Gonzalo Arroyo Ortega
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Gonzalo Arroyo Ortega shares her story.
Caregiver of the Month – April 2026: Gentry Trice
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Gentry Trice shares her story.
GIST Summit / GIST Day of Learning 2026
The GIST Summit 2026, held on March 21, at MD Anderson Cancer Center in Houston was a highly successful collaborative event that brought together approximately 125 patients, caregivers, medical professionals, and subject matter experts from across the country.
Histotripsy: What Patients Need to Know
Let's talk about histotripsy and sarcoma - what is the potential of this new procedure?
LRG on the Road: Representing the GIST Patient Voice in Texas
Simran Singh, Data Mgmt. & Research Manager, traveled to Texas to give a presentation on the LRG and the patient journey to trial investigators at GSK.
Patient of the Month – March 2026: Barney Mulvihill
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Barney Mulvihill shares his story.
What does an Expanded Access Program mean for GIST patients?
Pharmaceutical companies may create an Expanded Access Program (sometimes called compassionate use) when a clinical trial is no longer enrolling but the medicine still shows promise.
LRG & Collaborators Publish New Paper on Adjuvant Imatinib in KIT Exon 9 Mutations
Published on February 26, 2026, this international study represents a major collaboration between The Life Raft Group and thirty-five leading cancer centers across the U.S., Europe, and Japan to better understand treatment for gastrointestinal stromal tumors (GIST) with KIT exon 9 mutations.